November 5, 2025 — Leads & Copy — Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) will present data at the American Heart Association (AHA) Scientific Sessions showing that its PrecisionCHD test can detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA).
CHD, the most common CVD, is a leading cause of death in the U.S. While diagnosis typically focuses on obstructive forms, research indicates that a significant percentage of patients undergoing coronary angiography have INOCA, often observed in women, which frequently goes undiagnosed.
Dr. Robert Philibert, Chief Medical Officer, stated, “INOCA and MINOCA continue to pose a diagnostic challenge in modern cardiology,” noting that a tool like PrecisionCHD can help detect these conditions.
Dr. Philibert will present data from a University of Iowa study examining 267 patients hospitalized for acute coronary syndrome. The study found that methylation indices used in PrecisionCHD detected INOCA presentations with an overall AUC of 0.90, providing molecular phenotyping to inform care.
Tim Dogan, PhD, Chief Technology Officer, added that the findings validate the company’s epigenetic technology in detecting disease biology.
To schedule a meeting with Dr. Philibert at AHA Scientific Sessions, email support@cdio.ai.
Contact: support@cdio.ai
Source: Cardio Diagnostics
